Combined Treatment of Resistant Hypertension and Atrial Fibrillation
The Role of Renal Denervation in Improving Outcomes of Catheter Ablation in Patients With Refractory Symptomatic Atrial Fibrillation and Resistant Hypertension
Sponsor: Meshalkin Research Institute of Pathology of Circulation
Listed as NCT01117025, this PHASE2 trial focuses on Atrial Fibrillation and Hypertension, Resistant to Conventional Therapy and remains completed. Sponsored by Meshalkin Research Institute of Pathology of Circulation, it has been updated 6 times since 2010, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Apr 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Meshalkin Research Institute of Pathology of Circulation
For direct contact, visit the study record on ClinicalTrials.gov .